Drugs / ENA-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06967259 | May 2025 → Jul 2026 overdue | respiratory underresponsiveness to hypoxia and hypercapnia | Enalare Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06137638 | Dec 2026 → Jun 2027 expected | respiratory underresponsiveness to hypoxia and hypercapnia | Enalare Therapeutics Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENA-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06967259 ↗ |
| Known as | GAL-021 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068510 ↗ |
| Modality | Small molecule | — CHEMBL6068510 ↗ |
| Route | Intravenous | “ENA-001 is for IV injection ready for use per subject by the investigational pharmacy” NCT06137638 ↗ |